| NO | उत्पादों | CAS संख्या | प्रमुख गुणवत्ता संकेतक | |||
| पवित्रता | अधिकतम. अपवित्रता | कुल विलायक अवशेष | नमी | |||
| 1 | Fmoc-β-Ala-Ala-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 2 | Fmoc-D-Ala-D-Ala-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 3 | Fmoc-β-Ala-D-Ala-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 4 | एफएमओसी-आर्ग(पीबीएफ)-आर्ग(पीबीएफ)-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 5 | Fmoc-β-Ala-Arg(pbf)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 6 | एफएमओसी-डी-आर्ग(पीबीएफ)-डी-आर्ग(पीबीएफ)-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 7 | Fmoc-β-Ala-D-Arg(pbf)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 8 | एफएमओसी-होमोआर्ग(पीबीएफ)-होमोआर्ग(पीबीएफ)-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 9 | Fmoc-β-Ala-HomoArg(pbf)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 10 | एफएमओसी-एएसएन(टीआरटी)-एएसएन(टीआरटी)-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 11 | Fmoc-β-Ala-Asn(Trt)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 12 | एफएमओसी-एएसपी(ओटीबीयू)-एएसपी(ओटीबीयू)-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 13 | Fmoc-β-Ala-Asp(OtBu)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 14 | एफएमओसी-सीवाईएस(टीआरटी)-सीवाईएस(टीआरटी)-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 15 | Fmoc-β-Ala-Cys(Trt)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 16 | एफएमओसी-सीवाईएस(एसीएम)-सीवाईएस(एसीएम)-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 17 | Fmoc-β-Ala-Cys(Acm)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 18 | एफएमओसी-ग्लन(ट्रट)-ग्लन(ट्रट)-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 19 | Fmoc-β-Ala-Gln(Trt)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 20 | एफएमओसी-ग्लू(ओटीबीयू)-ग्लू(ओटीबीयू)-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 21 | Fmoc-β-Ala-Glu(OtBu)-OH.H2O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 22 | Fmoc-β-Ala-Gly-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 23 | एफएमओसी-हिस(ट्रट)-हिस(ट्रट)-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 24 | Fmoc-β-Ala-His(Trt)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 25 | Fmoc-Ile-Ile-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 26 | Fmoc-β-Ala-Ile-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 27 | Fmoc-Leu-Leu-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 28 | Fmoc-β-Ala-Leu-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 29 | Fmoc-D-Leu-D-Leu-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 30 | Fmoc-β-Ala-D-Leu-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 31 | एफएमओसी-लिस(बोक)-लिस(बोक)-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 32 | Fmoc-β-Ala-Lys(Boc)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 33 | एफएमओसी-लिस(एलोक)-लिस(एलोक)-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 34 | Fmoc-β-Ala-Lys(Alloc)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 35 | एफएमओसी-मेट-मेट-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 36 | Fmoc-β-Ala-Met-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 37 | Fmoc-Orn(Boc)-Orn(Boc)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 38 | Fmoc-β-Ala-Orn(Boc)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 39 | Fmoc-Phe-Phe-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 40 | Fmoc-β-Ala-Phe-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 41 | एफएमओसी-डी-फे-डी-फे-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 42 | Fmoc-β-Ala-D-Phe-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 43 | एफएमओसी-प्रो-प्रो-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 44 | Fmoc-β-Ala-Pro-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 45 | एफएमओसी-सेर(टीबीयू)-सेर(टीबीयू)-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 46 | Fmoc-β-Ala-Ser(tBu)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 47 | एफएमओसी-सेर(ट्रट)-सेर(ट्रट)-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 48 | Fmoc-β-Ala-Ser(Trt)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 49 | एफएमओसी-थ्र(टीबीयू)-थ्र(टीबीयू)-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 50 | Fmoc-β-Ala-Thr(tBu)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 51 | एफएमओसी-ट्रिप(बोक)-ट्रिप(बोक)-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 52 | Fmoc-β-Ala-Trp(Boc)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 53 | एफएमओसी-डी-ट्रिप(बोक)-डी-ट्रिप(बोक)-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 54 | Fmoc-β-Ala-D-Trp(Boc)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 55 | एफएमओसी-टायर(टीबीयू)-टायर(टीबीयू)-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 56 | Fmoc-β-Ala-Tyr(tBu)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 57 | एफएमओसी-डी-टायर(ईटी)-डी-टायर(ईटी)-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 58 | Fmoc-β-Ala-D-Tyr(Et)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 59 | Fmoc-Tyr(Me)-Tyr(Me)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 60 | Fmoc-β-Ala-Tyr(Me)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 61 | एफएमओसी-वैल-वैल-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 62 | Fmoc-β-Ala-Val-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 63 | एफएमओसी-डी-सीआईटी-डी-सीआईटी-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 64 | Fmoc-β-Ala-D-Cit-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 65 | Fmoc-β-Ala-Dab-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 66 | एफएमओसी-(3-(2-नैफ्थाइल)-डी-एला)2-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 67 | Fmoc-β-Ala-3-(2-naphthyl)-D-Ala-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 68 | एफएमओसी-(3-(3-पाइरिडिनिल)-डी-एला)2-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 69 | Fmoc-β-Ala-3-(3-पाइरिडिनिल)-D-Ala-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 70 | एफएमओसी-(4-क्लोरो-डी-फे)2-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 71 | Fmoc-β-Ala-4-क्लोरो-D-Phe-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 72 | एफएमओसी-(डी-4एपीएच(टीबीयूसीबीएम))2-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 73 | Fmoc-β-Ala-D-4Aph(tBuCbm)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 74 | एफएमओसी-एपीएच(एल-हॉर)-एपीएच(एल-हॉर)-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 75 | Fmoc-β-Ala-Aph(L-Hor)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 76 | एफएमओसी-लिस(iPr,Boc)-लिस(iPr,Boc)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 77 | Fmoc-β-Ala-Lys(iPr,Boc)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 78 | Fmoc-β-Ala-AEEA-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 79 | Fmoc-Aib-Aib-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 80 | Fmoc-β-Ala-Aib-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 81 | एफएमओसी-आर्ग-ओएच | 91000-69-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 82 | एच-आर्ग(पीबीएफ)-ओएच | 200115-86-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 83 | एफएमओसी-डी-आर्ग-ओएच | 130752-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 84 | HD-आर्ग(pbf)-OH | 200116-81-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 85 | एफएमओसी-होमोआर्ग-ओएच.एचसीएल | 208174-14-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 86 | H-होमोआर्ग(pbf)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 87 | एफएमओसी-डी-होमोआर्ग-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 88 | HD-होमोआर्ग(pbf)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 89 | एफएमओसी-एएसएन-ओएच | 71989-16-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 90 | H-Asn(Trt)-OH | 132388-58-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 91 | एफएमओसी-एएसपी-ओएच | 119062-05-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 92 | एच-एस्प(ओटीब्यू)-ओएच | 3057-74-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 93 | एफएमओसी-सीवाईएस-ओएच | 135248-89-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 94 | एच-सिस्ट(ट्रट)-ओएच | 2799/7/7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 95 | एच-सीवाईएस(एसीएम)-ओएच.एचसीएल | 28798-28-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 96 | एफएमओसी-ग्लन-ओएच | 71989-20-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 97 | H-Gln(Trt)-OH | 102747-84-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 98 | एफएमओसी-ग्लू-ओएच | 121343-82-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 99 | एच-ग्लू(ओटीब्यू)-ओएच.एच2ओ | 2419-56-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 100 | एफएमओसी-हिस-ओएच | 116611-64-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 101 | H-हिस(Trt)-OH | 35146-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 102 | बोक-हिस-ओएच | 17791-52-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 103 | एफएमओसी-लिस-ओएच | 105047-45-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 104 | H-लिस(बोक)-OH | 2418-95-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 105 | एच-लिस(एलोक)-ओएच | 6298/3/9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 106 | एफएमओसी-ओर्न-ओएच.एचसीएल | 201046-57-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 107 | H-ओर्न(बोक)-OH | 13650-49-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 108 | एफएमओसी-सेर-ओएच | 73724-45-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 109 | H-Ser(tBu)-OH | 18822-58-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 110 | H-Ser(Trt)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 111 | एफएमओसी-थ्र-ओएच.एच2ओ | 73731-37-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 112 | एच-थ्र(टीब्यू)-ओएच | 4378-13-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 113 | एफएमओसी-टीआरपी-ओएच | 35737-15-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 114 | H-ट्रिप(बोक)-OH | 146645-63-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 115 | एफएमओसी-डी-ट्रिप-ओएच | 86123-11-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 116 | एचडी-ट्रिप(बोक)-ओएच | 201290-11-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 117 | एफएमओसी-टायर-ओएच | 92954-90-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 118 | H-टायर(tBu)-OH | 18822-59-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 119 | एफएमओसी-डी-टायर-ओएच | 112883-29-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 120 | HD-टायर(एट)-ओएच | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 121 | H-टायर(Me)-OH.HCl | 67423-44-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 122 | एफएमओसी-डी-4एपीएच(सीबीएम)-ओएच | 324017-22-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 123 | HD-4Aph(tBuCbm)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 124 | एफएमओसी-लिस(iPr)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 125 | H-Lys(iPr,Boc)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
मुआवज़ा
जेंटोलेक्स उत्कृष्ट गुणवत्ता वाले उत्पाद प्रदान करता है, यदि ग्राहक द्वारा पर्याप्त साक्ष्य के साथ आवश्यक समय सीमा के भीतर किसी उत्पाद की गुणवत्ता पर सवाल उठाया जाता है, तो हम मुआवजे की प्रक्रियाओं को शुरू करने के लिए आवश्यक विश्लेषण और मूल्यांकन प्रदान करेंगे।
उत्पादन
दवा उत्पादों की क्षमता टन ग्रेड तक पहुंच गई, रासायनिक उत्पादों की क्षमता 100 टन+ ग्रेड तक पहुंच गई, क्षमताएं दुनिया भर में ग्राहकों की सेवा करने के लिए अच्छी तरह से सुसज्जित हैं।
अनुसंधान और विकास
हर साल, अनुसंधान एवं विकास टीम द्वारा विभिन्न नए उत्पादों को विकसित करने के लिए योजना बनाई जाती है, जब लक्ष्य निर्धारित किए जाते हैं, तो टीम के प्रत्येक सदस्य को KPI जिम्मेदारी और प्रोत्साहन नीति के साथ आगे बढ़ना होगा।